2023
Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey
Allen C, Snyder R, Horn D, Hudson M, Barber A, Smieliauskas F, Spears P, Edge S, Greenup R. Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey. JCO Oncology Practice 2023, 19: 932-938. PMID: 37651652, PMCID: PMC10615548, DOI: 10.1200/op.23.00159.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesInclusion of PROsQuality of lifePatients' QOLClinical trialsHealth care systemHealth system performanceCancer CenterCancer-related health care costsCare systemTherapeutic assessmentAcademic cancer centerEvidence-based careCancer clinical trialsDirect patient careHealth care costsNational Cancer InstituteOncologic outcomesOverall survivalMedical oncologistsCancer careOncology practiceCancer InstituteNonphysician providersCare costs
2022
Treatment patterns and medical costs of metastatic breast cancer care in the United States.
Jaber Chehayeb R, Hood A, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. DOI: 10.1200/jco.2022.40.16_suppl.e18834.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment patternsTreatment costsDiagnosis of MBCSocietal perspectiveHormone receptor statusBreast cancer careDays of diagnosisDe-identified databaseAverage wholesale priceElectronic health recordsMBC patientsMBC diagnosisReceptor statusCancer careInvasive cancerTriple NegativeClinical trialsReceptor subtypesPatient levelBreast cancerHuman epidermal growth factorPayer perspectiveDrug costsEpidermal growth factor
2019
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
Thornton M, Williamson H, Westbrook K, Greenup R, Plichta J, Rosenberger L, Gupta A, Hyslop T, Hwang E, Fayanju O. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals Of Surgical Oncology 2019, 26: 3166-3177. PMID: 31342392, PMCID: PMC6736696, DOI: 10.1245/s10434-019-07564-9.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyInvasive lobular carcinomaOverall survivalEndocrine therapyLobular carcinomaHormone receptor-positive groupNational Cancer Data BaseLower ratesPathologic complete responseKaplan-Meier curvesReceptor-positive groupCox proportional hazardsBackgroundNeoadjuvant chemotherapyCN1-3More comorbiditiesPostmastectomy radiationNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseClinical trialsBreast cancerCT classificationSmall tumorsProportional hazardsGreater burden
2016
A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer
Whitley M, Cardona D, Lazarides A, Spasojevic I, Ferrer J, Cahill J, Lee C, Snuderl M, Blazer D, Hwang E, Greenup R, Mosca P, Mito J, Cuneo K, Larrier N, O'Reilly E, Riedel R, Eward W, Strasfeld D, Fukumura D, Jain R, Lee W, Griffith L, Bawendi M, Kirsch D, Brigman B. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Science Translational Medicine 2016, 8: 320ra4. PMID: 26738797, PMCID: PMC4794335, DOI: 10.1126/scitranslmed.aad0293.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasLocal recurrenceTumor bedClinical trialsIntravenous injectionPhase 1 clinical trialHuman phase 1 clinical trialCo-clinical studiesMicroscopic residual cancerPositive surgical marginsFuture clinical trialsCo-clinical trialsRates of reexcisionAdjuvant therapyResidual cancerSurgical marginsTreatment failureTissue sarcomasBreast cancerCommon causeIntraoperative detectionMouse modelPharmacokinetic profileSolid tumorsCancer